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ABSTRACT
New 7-amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives, substituted at the 5-position with aryl(alkyl)a-
mino- and 4-substituted-piperazin-1-yl- moieties, were synthesized with the aim of targeting human (h)
adenosine A1 and/or A2A receptor subtypes. On the whole, the novel derivatives 1–24 shared scarce or no
affinities for the off-target hA2B and hA3 ARs. The 5-(4-hydroxyphenethylamino)- derivative 12 showed
both good affinity (Ki ¼ 150nM) and the best selectivity for the hA2A AR while the 5-benzylamino-substi-
tuted 5 displayed the best combined hA2A (Ki ¼ 123 nM) and A1 AR affinity (Ki ¼ 25nM). The 5-phenethyla-
mino moiety (compound 6) achieved nanomolar affinity (Ki ¼ 11nM) and good selectivity for the hA1 AR.
The 5-(N4-substituted-piperazin-1-yl) derivatives 15–24 bind the hA1 AR subtype with affinities falling in
the high nanomolar range. A structure-based molecular modeling study was conducted to rationalize the
experimental binding data from a molecular point of view using both molecular docking studies and
Interaction Energy Fingerprints (IEFs) analysis.
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Introduction
Adenosine receptors (ARs) are classified as A1, A2A, A2B and A3 sub-
types1,2 and typically inhibit (A1 and A3) or activate (A2A and A2B)
adenylyl cyclase. A1 receptor is highly expressed in brain areas,
such as the hippocampus and prefrontal cortex3,4, implicated in
the control of emotions and cognition functions. Therefore, A1 AR
antagonists are investigated as therapeutic agents for mental dys-
functions, such as dementia and anxiety3–5. The A2A AR subtype is
present in the brain with the highest concentration in the stri-
atum, nucleus accumbens, hippocampus and cortex, and its block-
ade has proven to be effective in neurodegenerative pathologies
such as Parkinson’s disease (PD)6–8. The A2A AR antagonist istrade-
fylline has been recently approved for marketing in Japan for the
treatment of PD patients9. In preclinical studies, dual A1/A2A antag-
onists have also turned out to be useful for PD therapy because
they reduce both motor (A2A) and cognitive (A1) impairment asso-
ciated with this pathology5,10–12.
Recent studies have highlighted new therapeutic applications
of A2A AR antagonists
12. If topically administered, they diminish
scar size and promote restoration of skin integrity13. A2A AR antag-
onists have also demonstrated efficacy in enhancing immunologic
response, especially by markedly improving anti-tumor immunity
in mouse models, thus promoting tumor regression. A2A AR antag-
onists have been shown to improve the effect of tumor vaccines
during T-cell activation, and may work in concert with other
immune checkpoint inhibitors in cancer immunotherapy12,14.
In our laboratory, much research has been addressed to the
study of AR antagonists belonging to different classes15–26, includ-
ing the 2-arylpyrazolo[4,3-d]pyrimidine derivatives20,22,24,26 which
display a broad range of affinity for the various AR subtypes,
depending on the nature of the substituents at the 5- and 7-
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positions of the bicyclic scaffold. One recent study aimed at target-
ing the A1 and A2A ARs highlighted that the presence of a free 7-
amino group, combined with a benzyl or, even better, a 3-phenyl-
propyl chain at the 5-position (Figure 1, compounds A and C)
shifted affinity toward these two AR subtypes24.
Hence, to further explore the structural requirements for
addressing affinity toward the A1 and/or A2A ARs, various aryl(alky-
l)amino- and 4-substituted-piperazin-1-yl- moieties were appended
at the 5-position of the scaffold (compounds 1–24, Figure 2).
These substituents were selected since they are a common feature
of potent A1 and/or A2A AR antagonists structurally correlated to
our pyrazolopyrimidine derivatives12,27,28 (such as the triazolotria-
zines ZM-241385 and D, Figure 1). The pyrazolopyrimidines 1–24
were tested in binding assays to evaluate their affinity at cloned
hA1, hA2A and hA3 ARs, stably expressed in CHO cells. Compounds
were also tested at the hA2B receptor by measuring their inhibi-
tory effects on NECA-stimulated cAMP levels in CHO cells.
A structure-based molecular modeling study was performed on
the new derivatives to rationalize the experimental binding data
from a molecular point of view, using molecular docking studies
in tandem with Interaction Energy Fingerprints (IEFs) analysis.
Chemistry
The 7-amino-pyrazolo[4,3-d]pyrimidine derivatives 1–14, bearing
an arylalkylamino moiety at the 5-position, were obtained as dis-
played in Scheme 1.
Both the 1-phenyl (26) and 1-alkyl substituted pyrazoles (27,
28) were synthesized from a common starting compound:
the readily available 4-nitro-1H-pyrazole-3-carbonitrile 2526 which
was a good substrate for both regioselective N-alkylation and N-
arylation. The latter was achieved by a cross-coupling reaction
with phenylboronic acid in the presence of cupric acetate and
activated molecular sieves. The 1-phenyl-pyrazole derivative 26
was thus prepared with higher yield than those previously
obtained in our laboratory through another synthetic pathway22.
The 1-methyl- and 1-benzyl-pyrazoles 27 and 28 were prepared
from compound 25 as already described26. The 4-nitropyrazolo-3-
carbonitriles 26–28 were transformed into the corresponding 4-
amino derivatives 29–3126 by reduction with cyclohexene and
Pd/C, under microwave-assisted conditions. Reaction of com-
pounds 29–31 with isothiocyanates in anhydrous DMF yielded
the corresponding N-(1-substituted-3-cyano-pyrazol-4-yl)thiourea
derivatives 32–42. Phenyl-, 4-methoxyphenyl-, 2,4-dichlorophenyl-
and benzyl-isothiocyanates were commercially available, the
others were synthesized as previously reported, i.e. allowing the
corresponding arylalkylamines to react with CS2, in 30% hydro-
gen peroxide aqueous solution (phenylethyl-, phenylpropyl- and
3,4-dimethoxyphenyl-isothiocyanates)29,30 or with thiophosgene
and potassium carbonate, in CH2Cl2 under nitrogen atmosphere
(4-methoxyphenylisothiocyanate)31.
Compounds 32–42 were reacted with iodomethane in
anhydrous DMF to give the corresponding S-methylisothiourea
derivatives 43–53 which were cyclized to the desired 7-amino-5-
arylalkylamino-pyrazolo[4,3-d]pyrimidines 1–3, 5–12 by reaction
with ammonium chloride in formamide, under microwave irradi-
ation. The methoxy-substituted derivatives 2, 11 and 12 were
transformed into the corresponding hydroxy derivatives 4, 13 and
14 by treatment with BBr3 in anhydrous CH2Cl2.
Figure 2. Herein reported pyrazolo[4,3-d]pyrimidine derivatives 1–24.
Figure 1. Previously reported pyrazolo[4,3-d]pyrimidines A–C and triazolotria-
zines ZM-241385 and D.
R R2 R R2
32, 43, 1 Ph Ph 38, 49, 8 Ph Me
33, 44, 2 4-OMe-C6H4 Ph 39, 50, 9 Ph-CH2 Me
34, 45, 3 2,4-diClC6H3 Ph 40, 51, 10 Ph-CH2 CH2Ph
4 4-OH-C6H4 Ph 41, 52, 11 4-OMe-C6H4-(CH2)2 Ph
35, 46, 5 Ph-CH2 Ph 42, 53, 12 3,4-diOMe-C6H3-(CH2)2 Ph
36, 47, 6 Ph-(CH2)2 Ph 13 4-OH-C6H4-(CH2)2 Ph
37, 48, 7 Ph-(CH2)3 Ph 14 3,4-diOH-C6H3-(CH2)2 Ph
Scheme 1. Reagents and conditions: (a) Ph-B(OH)2, Cu(OAc)2, pyridine, CH2Cl2,
4 Å molecular sieves, room temperature; (b) MeI or PhCH2Br, NaH, anhydrous THF,
room temperature; (c) cyclohexene, Pd/C, 150 C, mw; (d) R–N¼C¼S, DMF, room
temperature; (e) 0.1 M aqueous NaOH, CH3I, room temperature; (f) NH4Cl, forma-
mide, 110–150 C mw; (g) compounds 2, 11, 12, BBr3, anhydrous CH2Cl2, room
temperature or reflux.
R
15, 57 Ph
16, 58 CH2Ph
17, 59 (CH2)2Ph
18, 60 CH2C6H2-2,4,6-F
19, 61 CH2C6H3-2-Cl-4-F
20, 62 CO(2-furyl)
21, 63 COOtBu
22 CH2(2-furyl)
Scheme 2. Reagents and conditions: (a) N,N-dimethylaniline, POCl3, 150 C, mw;
(b) 33% aqueous NH3, 100 C, mw; (c) benzylamine, ethyldiisopropylamine, tert-
butanol, 200 C, mw; (d) ethyldiisopropylamine, N-methylpyrrolidone, 130–150 C,
mw; (e) compound 20, LiAlH4, anhydrous THF, room temperature.
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The 7-amino-pyrazolo[4,3-d]pyrimidine derivatives 15–22, bear-
ing N-substituted-piperazine moieties at the 5-position, were
obtained utilizing the synthetic route as described in Scheme 2.
Allowing the 1-phenylpyrazolo[4,3-d]pyrimidine-5,7-dione 5420
to react with phosphorus oxychloride and N,N-dimethylaniline
under microwave irradiation, the 5,7-dichloro-derivative 55 was
prepared, which was reacted with 33% aqueous ammonia solution
under microwave irradiation at 100 C to give the 7-amino-
5-chloro-pyrazolopyrimidine 56 as the only regioisomer. The
7-amino structure of 56 was expected on the basis of the well-
known different mobility of the two chlorine atoms in the pyrimi-
dine ring, also condensed with diverse heterocyclic systems32–34.
To confirm the structure, derivative 56 was treated with benzyl-
amine in tert-butanol, in the presence of diisopropylethylamine,
and the 7-amino-5-benzylaminopyrazole derivative 5, already syn-
thesized through the unambiguous synthesis as depicted in
Scheme 1, was obtained. This reaction was carried out under pro-
longed microwave irradiation (about 1 h at 200 C) but conversion
of derivative 56 into 5 occurred with unsatisfactory yields. The 1H
NMR spectrum of the crude reaction (data not shown) displayed
the presence of both the 5-benzylamino derivative 5 and the start-
ing material 56 (ratio about 3.5:1), besides degradation compounds,
thus indicating the poor reactivity of the C5 atom toward the pri-
mary benzyl ammine group. Instead, microwave-assisted reaction
of the 5-chloro derivative 56 with the N-substituted piperazines
57–63, in N-methylpyrrolidone and in the presence of diisopropyle-
thylamine, proceeded to completion, thus giving the desired pyra-
zolopyrimidine derivatives 15–20 with good yields (48–85%). The
piperazine derivatives 57, 58, 62 and 63 were commercially avail-
able, while derivatives 59 and 61 were prepared as previously
described35,36. The piperazine derivative 60 was synthesized start-
ing from the reductive alkylation of N-Boc-piperazine 63 with 2,4,6-
trifluorobenzaldeyde and triacetoxy sodium borohydride. The
obtained tert-butyl 4-(2,4,6-trifluorobenzyl)piperazine-1-carboxylate
was hydrolyzed with trifluoroacetic acid to give the 1-(2,4,6-trifluor-
obenzyl)piperazine 60, isolated as trifluoroacetate salt.
Reduction of the 2-furoyl carbonyl group of compound 20 with
LiAlH4 in anhydrous THF provided derivative 22. Finally, the
Scheme 3. Reagents and conditions: (a) CF3COOH, CH2Cl2, reflux; (b) RCOCl, NEt3,
anhydrous THF, room temperature.
Table 1. Binding affinity at hA1, hA2A and hA3 ARs and potencies at hA2B ARs.
Binding experimentsa
Ki (nM) or I%
cAMP assays IC50 (nM)
or I%
R R2 hA1
b hA2A
c hA3
d hA2B
e
1 Ph Ph 67 ± 5 412 ± 37 13 ± 2 2%
2 4-OMe-C6H4 Ph 33% 8% 27± 3 1%
3 2,4-diClC6H3 Ph 1% 1% 61± 8 2%
4 4-OH-C6H4 Ph 481 ± 42 40% 8% 10%
5 Ph-CH2 Ph 25 ± 3 123 ± 11 28 ± 3 2%
6 Ph-CH2CH2 Ph 11.5 ± 1.2 40% 38% 1%
7 Ph-CH2CH2CH2 Ph 785 ± 72 29% 24% 1%
8 Ph Me 1% 4% 1% 1%
9 Ph-CH2 Me 9% 1% 20% 1%
10 Ph-CH2 CH2Ph 19% 1% 1% 1%
11 4-OMe-C6H4-CH2CH2 Ph 153 ± 11 26% 19% 1%
12 4-OH-C6H4-CH2CH2 Ph 27% 150 ± 14 1% 1%
13 3,4-diOMe-C6H3-(CH2)2 Ph 415 ± 39 189 ± 18 22% 17%
14 3,4-diOH-C6H3-(CH2)2 Ph 71 ± 6 238 ± 24 3% 1%
Af Ph – 150 ± 12 110 ± 10 39% 420 ± 38
Bf Ph-CH2 – 15% 35% 17% 2%
Cf Ph-CH2CH2 – 5.31 ± 0.42 55 ± 5 12% 42%
ZM-241385g – 714 1.6 743 75h
aKi values are means ± SEM of four separate assays each performed in duplicate. Percentage of inhibition (I%) are determined at 1 lM concentration of the tested
compounds.
bDisplacement of specific [3H]DPCPX competition binding assays to hA1CHO cells.
cDisplacement of specific [3H]ZM241385 competition binding to hA2ACHO cells.
dDisplacement of specific [125I]AB-MECA competition binding to hA3CHO cells.
ecAMP experiments in hA2BCHO cells, stimulated by 200 nM NECA. Percentage of inhibition (I%) are determined at 1 lM concentration of the tested compounds.
fRef. 24.
gRef. 5.
hKi value obtained from binding experiments at recombinant hA2B.
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pyrazolopyrimidines 23–24, bearing an acyl moiety on the pipera-
zine nitrogen, were synthesized as depicted in Scheme 3.
Treatment of the N-Boc derivative 21 with trifluoroacetic acid fur-
nished compound 64 which was reacted with suitable acyl chlor-
ides, in the presence of triethylamine in anhydrous
tetrahydrofuran, to provide the desired 23–24.
Results and discussion
Structure–affinity relationship studies
The results of binding experiments and cAMP assays carried out
on the new 5-substituted-pyrazolopyrimidines 1–14 and 15–24
are displayed, respectively, in Tables 1 and 2. Table 1 also includes
the affinity data of the pyrazolopyrimidines A–C and of ZM-
241385 reported as references.
As expected, the new derivatives 1–24 shared scarce or no
affinities for the off-target hA2B and hA3 ARs, except the 5-anilino-
and 5-benzylamino derivatives 1–3 and 5, respectively which dis-
played nanomolar affinity for the hA3 subtype (Ki ¼ 13–61 nM). In
particular, compounds 2 and 3 are worth noting, being also highly
hA3 selective.
Since the purpose of the work was to target hA1 and hA2A ARs,
SAR discussion was focused on hA1 and hA2A binding data. In this
respect, results of some interest have been obtained from the 5-
arylalkylamino-pyrazolopyrimidines 1–14. In fact, compound 12
showed both good affinity and the best selectivity for the hA2A
AR, while compounds 1, 5, 13 and 14 were able to bind both the
hA1 and hA2A ARs. Moreover, a derivative having nanomolar affin-
ity and high selectivity for the hA1 AR subtype was identified
(compound 6).
The new 5-phenyl(alkyl)amino derivatives 1, 5 and 6 were
designed as analogs of our previously reported antagonists 5-phe-
nyl(alkyl) derivatives A, B and C24 whose methylene linker at the
5-position of the bicyclic core was replaced with an NH. This modi-
fication, suggested by the structure of potent A2A antagonists
bearing arylalkylamino moieties as key substituents12, was thought
to change the flexibility of the 5-lateral chain and, hopefully, to
increase the affinity for the targeted ARs. Actually, the NH linker
enhanced the hA1 AR affinity (compare 1 and 5 to A and B,
respectively) or maintained it in the nanomolar range (compare 6
to C). Instead, the hA2A AR binding was ameliorated in one case,
i.e. the 5-benzylamino derivative 5 which was more active than
the corresponding phenylalkyl-derivative B.
Analyzing the hA1 and hA2A AR binding data of 1–6 in detail, it
can be observed that 5-phenylamino derivative 1 binds to the
hA2A and hA1 AR subtypes with scarce (Ki¼ 412 nM) and good
affinity (Ki¼ 67 nM), respectively. Introduction of either a 4-
methoxy group or 2,4-dichloro substituents on the 5-aniline moi-
ety of 1 (compounds 2 and 3) dropped affinity for hA1 and hA2A
ARs. Instead, the presence of a 4-hydroxy residue (compound 4)
reduced the hA2A affinity while conserving some ability to bind
the hA1 receptor (Ki¼ 481 nM). Homologation of the 5-phenyla-
mino moiety (derivative 1) to the 5-benzylamino group (derivative
5) produced some improvement in the binding activity at both
hA1 (Ki¼ 25 nM) and hA2A ARs (Ki ¼ 123 nM). Quite unexpectedly,
homologation of the alkyl chain of compound 5, to obtain the 5-
phenethylamino- and the 5-phenylpropylamino derivatives 6 and
7, caused a drastic reduction of the hA2A AR affinity and, in the
former, it increased the hA1 one, thus affording a selective hA1
receptor ligand (Ki¼ 11.5 nM).
Replacement of the 2-phenyl group of derivatives 1 and 5 with
a methyl residue, to give compounds 8 and 9, was performed to
verify whether a reduction in the volume of the molecule might
permit a better accommodation inside the recognition site of the
targeted hARs. This modification, instead, annulled the capability
to bind the target hARs. The same detrimental effect was obtained
when the 2-phenyl ring of 5 was replaced with the more flexible
benzyl moiety (derivative 10).
Insertion of the para hydroxy substituent on the 5-phenethyla-
mino moiety of derivative 6, to give compound 12, was based on
the structure of the well-known potent and selective hA2A AR
antagonist ZM-2413855,12 (Figure 1). Accordingly, we also thought
it would be interesting to evaluate the 3,4-dihydroxy substitution
(compound 14), as well as the 4-methoxy- and the 3,4-dimethoxy-
substituents (derivatives 11 and 13). As expected, the presence of
the 4-hydroxy group was able to shift the affinity toward the hA2A
AR. In fact, the 4-hydroxy-substituted derivative 12 showed good
hA2A affinity (Ki¼150 nM) and the best selectivity among all the
ligands reported here. In contrast, reversed selectivity was demon-
strated by the 4-methoxy derivative 11, which displayed good
affinity for the hA1 AR but not for the hA2A subtype. Instead, the
3,4-dimethoxy substituted derivative 13 bound both hA1 and hA2A
receptors and also the 3,4-dihydroxy derivative 14 showed
quite good affinity for both the receptors, but especially for the
hA1 one.
Finally, to further explore the SARs in this class of AR ligands,
various N-substituted piperazine moieties were appended at the
5-position (derivatives 15–24, Table 2), in accordance with the
structure of known potent and selective hA2A AR antagonists
27,28.
In contrast to our expectations, none of the 5-(N4-R-piperazin-
1-yl) derivatives 15–24 were able to bind effectively the A2A AR
while they possessed affinity for the hA1 AR subtype, falling in the
high nanomolar range. The most active compounds proved to be
22 (Ki¼ 92 nM) and 16 (Ki¼162 nM) which bear, respectively, the
(2-furyl)-methyl and 2-benzyl pendant on the N4-piperazine moi-
ety. Introduction of halogen atoms on the benzyl moiety of 16 left
almost unchanged the hA1 AR affinity (compounds 18 and 19)
Table 2. Binding affinity at hA1, hA2A and hA3 ARs and potencies at hA2B ARs.
Binding experimentsa
Ki (nM) or I% cAMP assays I%
R hA1
b hA2A
c hA3
d hA2B
e
15 Ph 647 ± 53 20% 20% 1%
16 CH2Ph 162 ± 14 1% 1% 1%
17 (CH2)2Ph 518 ± 42 40% 40% 1%
18 CH2C6H2-2,4,6-F 204 ± 18 34% 39% 1%
19 CH2C6H3-2-Cl-4-F 193 ± 17 29% 1% 2%
20 CO-2-furyl 580 ± 47 16% 13% 2%
21 COOtBu 615 ± 49 33% 21% 1%
22 CH2-2-furyl 92 ± 8 38% 5% 16%
23 COCH2tBu 29% 2% 1% 2%
24 COCH2Ph 429 ± 36 3% 1% 3%
aKi values are means ± SEM of four separate assays each performed in duplicate.
Percentage of inhibition (I%) are determined at 1 lM concentration of the
tested compounds.
bDisplacement of specific [3H]DPCPX competition binding assays to hA1CHO
cells.
cDisplacement of specific [3H]ZM241385 competition binding to hA2ACHO cells.
dDisplacement of specific [125I]AB-MECA competition binding to hA3CHO cells.
ecAMP experiments in hA2BCHO cells, stimulated by 200 nM NECA. Percentage of
inhibition (I%) are determined at 1 lM concentration of the tested compounds.
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while elongation of the benzyl chain decreased it (compound 17).
Also the other substituents evaluated on the piperazine ring,
i.e. acyl moieties (derivatives 20, 23, 24) and the tert-butoxycar-
bonyl group (derivative 21) did not ameliorate the hA1 AR
affinities.
Molecular modeling studies
A structure-based molecular modeling study was conducted to
rationalize the experimental binding data from a molecular point
of view. Minor attention was devoted to the hA2B AR subtype,
since no significant binding affinity has been estimated for any of
the compounds under investigation. Docking was performed on
hA1, hA2A and hA3 AR subtypes, and the resulting poses were
evaluated according to the van der Waals and electrostatic interac-
tions, as previously reported37,38 and described in detail in the
“Experimental” section. Positive electrostatic and van der Waals
values were used as filters to reject unfavorable docking poses.
One pose for each ligand was selected on the basis of the
Interaction Energy Fingerprints (IEFs) and by visual inspection.
An overview of the most favorable poses of all compounds on
hA1, hA2A and hA3 ARs is reported in video SM1-SM2-SM3,
included in Supplementary Material. The heat map depicted in the
background reports the electrostatic and hydrophobic contribu-
tions of the residues mainly involved in binding (“ele” and “hyd”
labels identify the major contribution type of the residue) by a col-
orimetric scale going from blue to green for negative to positive
values. These crucial residues are mainly positioned on the super-
ior half of TM6 and TM7 and EL2, and the overall binding modes
of the compounds under examination are very consistent among
them. Here, we describe in detail the poses of compound 1 as an
example, because of its high binding affinity for all three AR sub-
types taken into consideration (Ki ¼ 67 nM for hA1, Ki ¼ 412 nM for
hA2A and Ki ¼ 13 nM for hA3).
Figure 3. Interaction Energy Fingerprints (IEFs) comparison between compound 1 and compound ZM-241385 used as reference. Panels A, B and C report the compari-
son analysis for hA1, hA2A and hA3 receptor subtypes, respectively. On the left side is shown the electrostatic contribution comparison, while on the right the hydropho-
bic one. In each subsection, the IEFs of compound 1 are shown above the IEFs of the reference ZM-241385.
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With regard to the hA1 AR, Glu172 (EL2) and Asn254 (6.55), rep-
resented by blue bars on electrostatic IEFs (Figure 3, panel A on
the left), emerge as important residues for electrostatic contribu-
tion, together with a slight contribution of Trp247 (6.48) and
His251 (6.52). Asn254 (6.55) and Glu172 (EL2) are engaged in a
three hydrogen bond pattern with N1 of pyrazole and with the
exocyclic amine group at position 7 of compound 1, as shown in
Figure 4, panel A. The aromatic pyrazolopyrimidine scaffold is
involved in a p–p stacking interaction with Phe171 (EL2), which is
one of the residues appearing to have the strongest hydrophobic
interaction on the hydrophobic IEFs (green bars in Figure 3, panel
A on the right). Val87 (3.32), Leu88 (3.33), Trp247 (6.48), Leu250
(6.51), Tyr271 (7.36) and Ile274 (7.39) are also involved in signifi-
cant hydrophobic contacts, with Val87 (3.32), Leu88 (3.33), Trp247
(6.48) defining the bottom of the binding pocket.
The residues involved in binding at hA2A AR are positioned
equivalently to those just described for the hA1 subtype. Glu169
(EL2) and Asn253 (6.55) are involved in hydrogen bonds and
Phe168 (EL2) makes a p–p stacking interaction, as can be seen in
Figure 4, panel B. Trp246 (6.48) and His250 (6.52), together with
Glu169 and Asn253, give stabilizing electrostatic contributions to
the binding of 1, while Leu85 (3.33), Leu167 (EL2), Phe168 (EL2),
Trp246 (6.48), Leu249 (6.51), Tyr271 (7.36) are interested by hydro-
phobic contacts (Figure 3, panel B).
The binding of compound 1 to the hA3 subtype mainly
engages Trp243 (6.48), Ser247 (6.52) and Asn250 (6.55) for electro-
static interactions, and Leu91 (3.33), Phe168 (EL2), Val169 (EL2),
Trp243 (6.48), Leu246 (6.51), Leu264 (7.35), Tyr265 (7.36), Ile268
(7.39) for hydrophobic interactions, as can be seen in Figure 3,
panel C. In this case only Asn250 can be involved in the hydrogen
bond network (Figure 4, panel C), since in the A3 AR the position
equivalent to Glu172 of the hA1 and Glu169 of the A2A AR is occu-
pied by Val169, which cannot establish a hydrogen bond with the
amino group at position 5 of compound 1.
Most of the poses resemble the conformation that ZM-241385
assumes in the binding site of the hA2A AR crystal structure and of
hA1 and hA3 AR models. The benzene ring at position 2 occupies
the position of the furan ring of ZM-241385, the 7-amino-pyrazolo-
pyrimidine scaffold is well superimposed on the reference 7-
amino-triazolotriazine and the arylalkylamino group at position 5
points in the same direction as the para-hydroxyphenyl-ethyla-
mino fragment. The similarity of the binding modes confirms the
expectation provided by the IEFs comparison between 1 and ZM-
241385 (Figure 3, panels A, B and C). To quantitatively compare
the calculated IEFs profiles, two novel analyses have been pro-
posed called RMSD and RMSDtrend analysis (see the Experimental
Section for more details). In the case of derivative 1 both RMSD
and RMSDtrend between electrostatic and hydrophobic IEFs on
each hAR subtype are quite low. However, the electrostatic RMSD
(2.18 kcal/mol) and the electrostatic RMSDtrend (0.47 kcal/mol) for
the hA1 subtype are higher than the values observed for hA2A and
hA3 ARs. This does not seem to fit with the low Ki (67 nM) for the
hA1 receptor; however, it appears that the major unfavorable con-
tribution is provided by Glu170, which may probably be corrected
by a slight rotation of the phenyl group of the compound.
Subsequently, we compared the binding behavior of com-
pound 1 to that of its analog derivative A (Ki ¼ 150 nM for hA1,
Ki¼110 nM for hA2A and I%¼ 39 at 1mM for hA3), having a methy-
lene instead of the NH linker at the 5-position. The IEFs compari-
son did not allow a complete rationalization of the different
selectivity profiles of compounds 1 and A (Figure SM1).
Electrostatic RMSD and RMSDtrend values on the hA3 receptor (1.10
and 0.18 kcal/mol, respectively) are higher than those of com-
pound 1 (0.60 and 0.06 kcal/mol, respectively), in accordance with
the lower potency of derivative A (I ¼ 39% at 1 mM) compared
with 1 (Ki¼ 13 nM). On the other hand, we have to honestly
observe that also compound A presents higher RMSD and
RMSDtrend values (1.49 and 0.18 kcal/mol, respectively) on the hA2A
receptor as compared with compound 1 (0.96 and 0.08 kcal/mol,
respectively), but in this case the affinity of the former (110 nM) is
higher than that of the latter (412 nM). The result of the IEFs com-
parison is confirmed by the similarity of the binding modes of
derivatives 1 and A at all receptor binding sites, as reported in
Figure 4 (panels A, B and C). In this case docking is not sufficient
to rationalize the difference in binding affinities. In fact, the mere
examination of the final state of the binding process may not be
sufficient to explain differences in the activity or selectivity pro-
files. The presence of water molecules and the entropic effect are
only two among the pool of binding contributions that we are
not taking into consideration during our docking simulations.
Similar considerations can be made observing the results of
IEFs comparison for all the dataset compounds on the different AR
subtypes (Figure 5). We would have expected to find blue and red
rectangles associated with good and bad binders, respectively, but
Figure 4. Comparison of the proposed binding mode of compound 1 (sky blue), compound A (pink), and reference pose of ZM-241385 (green) on hA1, hA2A and hA3
subtype receptors (panels A, B and C, respectively). Protein residues mainly involved in binding are shown as sticks (tan). The zoom makes TM1 not visible, while TM6
and TM7 are rendered in a transparent manner to give a more clear visualization of the binding site.
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this prevision was not satisfied: a major similarity of the IEFs
between the target and the reference compounds are not always
related to good binding affinity of the ligand. However, an inter-
esting example is provided by compounds 8, 9 and 10, which
have no affinity for any of the receptors. Red rectangles cross hori-
zontally almost the whole hydrophobic RMSD and RMSDtrend table,
meaning that there is a considerable loss in the binding hydro-
phobic contribution in comparison with the reference. As a control
experiment, ZM-241385 has been docked into the three AR sub-
types, the IEFs have been computed for the selected poses and
compared with that of the reference pose of ZM241385: as
expected, the electrostatic and hydrophobic RMSD and RMSDtrend
values are close to zero (Figure 5).
The 5-(N4-R-piperazin-1-yl) compounds 15–24 are hA1 AR
selective. These derivatives find a steric hindrance in the hA3 bind-
ing site and the van der Waals values of the selected poses are
positive (as indicated by exclamation points in Figure 5). However,
from the IEFs comparison analysis (Figure 5), we would have pre-
dicted a hA2A versus hA1 selectivity (blue versus red rectangles). In
fact, while at the hA2A binding site the predicted poses of these
compounds behave like ZM-241385, at the hA1 binding site they
deviate a little from the reference position, losing some of the
canonical interactions (Video SM1-SM2). Interestingly, this diver-
sion results in a gain for compounds 16, 17, 18, 19 and 22: the
protonated amine at position 4 of the piperazine moiety is
involved in an ionic interaction with Glu170 (EL2), which is con-
firmed by a highly negative electrostatic contribution reported on
the heat map in the background of Video SM1. The absence of a
negatively charged residue at a position equivalent to Glu170 on
hA2A (Leu167) and hA3 (Gln167) receptors may be associated with
the hA1 selectivity of these compounds.
Conclusion
The herein reported structural investigation was carried out to
identify new antagonists targeting the hA2A AR or both the hA1/
hA2A ARs. Hence, various arylalkylamino- and 4-substituted-pipera-
zin-1-yl- moieties were appended at the 5-position of the pyra-
zolo[4,3-d]pyrimidine scaffold. The 4-hydroxyphenylethylamino
group was the most profitable, since the ZM-241385-based com-
pound 12 showed both good hA2A affinity (Ki ¼ 150 nM) and the
highest selectivity among all the ligands reported here. The 5-ben-
zylamino moiety (compound 5) achieved the best combined hA2A
(Ki ¼ 123 nM) and hA1 affinity (Ki ¼ 25 nM) while the 5-phenethyla-
mino pendant (compound 6) afforded nanomolar affinity (Ki
¼ 11 nM) and good selectivity for the hA1 AR. The 5-(N4-substi-
tuted-piperazin-1-yl) derivatives 15–24 were inactive at the hA2A
AR while the hA1 affinities spanned the high nanomolar range.
These outcomes provide new insights about the structural require-
ments of our pyrazolopyrimidine series for hA2A- and hA1-receptor
ligand interaction. Nevertheless, the obtained results do not
prompt us to synthesize further derivatives of this series featured
by 5-arylalkyamino- and 5-piperazino- moieties.
A structure-based molecular modeling study was conducted to
rationalize the experimental binding data from a molecular point
of view using molecular docking studies in tandem with Interaction
Energy Fingerprints (IEFs) analysis. Moreover, to quantitatively com-
pare IEFs profiles and, consequently, to address the similarity of the
binding modes of different compounds in different receptor sub-
types, two novel analyses have been proposed, called RMSD and
RMSDtrend analyses. Even if, we are conscious that the simple
inspection of the final state of the binding process may not be suf-
ficient to explain differences in the activity or selectivity profiles,
these novel tools can facilitate the mode of representation and
interpretation of the docking data obtained by analyzing simultan-
eously several compounds against different receptor subtypes.
Experimental section
Chemistry
The microwave-assisted syntheses were performed using an
Initiator EXP Microwave Biotage instrument (frequency of
Figure 5. Results of the IEFs comparison between all compounds and reference compound ZM-241385. RMSDs and RMSDtrend between electrostatic (panels A and B,
respectively) and hydrophobic (panels C and D, respectively) Energy Fingerprints of each compound (y-axis) and reference ZM-241385 are reported for hA1, hA2A and
hA3 receptors (x-axis). A colorimetric scale going from blue to red represents favorable to unfavorable values. An exclamation point identifies those poses that have a
positive van der Waals and/or electrostatic potential (and for which was not possible to select an alternative pose with negative values).
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irradiation: 2.45GHz). Analytical silica gel plates (Merck F254), pre-
parative silica gel plates (Merck F254, 2mm) and silica gel 60
(Merck, 70–230 mesh) were used for analytical and preparative
TLC, and for column chromatography, respectively. All melting
points were determined on a Gallenkamp melting point apparatus
and are uncorrected. Elemental analyses were performed with a
Flash E1112 Thermofinnigan elemental analyzer for C, H, N and
the results were within ±0.4% of the theoretical values. All final
compounds revealed a purity not less than 95%. The IR spectra
were recorded with a Perkin-Elmer Spectrum RX I spectrometer in
Nujol mulls and are expressed in cm1. The 1H NMR spectra were
obtained with a Bruker Avance 400MHz instrument. The chemical
shifts are reported in d (ppm) and are relative to the central peak
of the solvent which was CDCl3 or DMSO-d6. The assignment of
exchangeable protons (OH, and NH) was confirmed by addition of
D2O. The following abbreviations are used: s ¼ singlet, d
¼doublet, t ¼ triplet, m ¼multiplet, br ¼broad and ar ¼ aromatic
protons.
4-Nitro-1-phenyl-1H-pyrazole-3-carbonitrile 2626
The title compound was prepared with a different procedure
from that previously described by us26. Briefly, phenylboronic
acid (2.4mmol), cupric acetate (1.8mmol) and activated 4 Å
molecular sieves (750mg) were added to a solution of 4-nitro-
1H-pyrazole-3-carbonitrile26 (1.2mmol) in anhydrous dichlorome-
thane (8mL) and pyridine (2.4mmol). The mixture was stirred at
room temperature, under air, in a loosely capped flask for two
days, then it was diluted with chloroform (20–30mL) and filtered
through celite. The solution was extracted with 0.1 M HCl (15ml
for three times), the organic phase was anhydrified (Na2SO4) and
evaporated at reduced pressure to give a solid which was col-
lected by suction, washed with water and then cyclohexane and
recrystallized. Yield 75%; m.p. 143–145 C (cyclohexane/EtOH); 1H
NMR (DMSO-d6) 7.54–7.63 (m, 3H, ar), 7.74–7.76 (m, 2H, ar), 8.71
(s, 1H, H-5).
General procedure for the synthesis of 3-substituted-1-(3-cyano-1-
R2–1H-pyrazol-4-yl)thioureas 32–42
The commercially available phenyl-, 4-methoxyphenyl-, 2,4-dichlor-
ophenyl- and benzyl-isothiocyanates or the suitably synthesized
phenethyl-29, 4-methoxyphenethyl-31, 3,4-dimethoxyphenethyl-30,
phenylpropyl-isothiocyanates29 (1.97mmol) were added to a solu-
tion of the 1-substituted-4-amino-pyrazole-3-carbonitriles 29–3126
(1.64mmol) in anhydrous DMF (1.5mL). The mixture was stirred at
room temperature for 3–4 h (compounds 32–34, 38, 39), for 16 h
(compounds 35, 40, 42) and for 24 h (compounds 36, 37, 41).
The obtained dark slurry was treated with water (20mL) and, in
the case of compounds 33–35 and 39, a solid precipitated which
was collected by filtration. For derivatives 32, 36–38, 40–42, the
aqueous mixture was extracted with EtOAc (30mL 3). The com-
bined organic extracts were anhydrified (Na2SO4) and the solvent
evaporated at reduced pressure. The obtained solid was treated
with Et2O (5–10mL) and isolated by filtration. Crude compound
42 was purified by column chromatography (eluent:cyclohexane/
EtOAc/MeOH 6:4:1). Derivatives 32, 38–40, as well as 42, were
unstable upon recrystallization, hence they were used as such for
the next step.
1-(3-Cyano-1-phenyl-1H-pyrazol-4-yl)-3-phenylthiourea 32 Yield
89%; 1H NMR (DMSO-d6) 7.19 (t, 1H, ar, J¼ 7.4 Hz), 7.36 (t, 2H, ar,
J¼ 7.6 Hz), 7.46 (t, 1H, ar, J¼ 7.4 Hz), 7.51 (d, 2H, ar, J¼ 7.6 Hz),
7.58 (t, 2H, ar, J¼ 7.5 Hz), 7.88 (d, 2H, ar, J¼ 7.7 Hz), 8.97 (s, 1H,
pyrazole proton), 9.68 (br s, 1H, NH), 10.04 (br, s, 1H, NH).
1-(3-Cyano-1-phenyl-1H-pyrazol-4-yl)-3-(4-methoxyphenyl)thiourea
33 Yield 95%; m.p. 165–167 C (cyclohexane/EtOAc); 1H NMR
(DMSO-d6) 3.75 (s, 3H, OCH3), 6.95 (d, 2H, ar, J¼ 8.9 Hz), 7.33 (d,
2H, ar, J¼ 8.9 Hz), 7.46 (t, 1H, ar, J¼ 7.6 Hz), 7.58 (t, 2H, ar,
J¼ 7.3 Hz), 7.89 (d, 2H, ar, J¼ 7.6 Hz), 8.95 (s, 1H, pyrazole proton),
9.56 (br s, 1H, NH), 9.89 (br s, 1H, NH). Anal. Calc. for C18H15N5OS.
1-(3-Cyano-1-phenyl-1H-pyrazol-4-yl)-3-(2,4-dichlorophenyl)thiourea
34
Yield 98%; m.p. 166–169 C (cyclohexane/EtOAc); 1H NMR (DMSO-
d6) 7.44–7.60 (m, 5H, ar), 7.80 (s, 1H, ar), 7.96 (d, 2H, ar, J¼ 7.9 Hz),
9.02 (s, 1H, pyrazole proton), 9.82 (br s, 1H, NH), 9.98 (br s, 1H,
NH). Anal. Calc. for C17H11Cl2N5S.
1-Benzyl-3-(3-cyano-1-phenyl-1H-pyrazol-4-yl)thiourea 35 Yield
74%; m.p. 180–183 C (EtOH). 1H NMR (DMSO-d6) 4.75 (d, 2H, CH2,
J¼ 4.6 Hz), 7.26–7.34 (m, 5H, ar), 7.45 (t, 1H, ar, J¼ 7.3 Hz), 7.57 (t,
2H, ar, J¼ 7.4 Hz), 7.87 (d, 2H, ar, J¼ 8.1 Hz), 8.49 (br s, 1H, NH),
8.99 (s, 1H, H-5), 9.55 (br s, 1H, NH). Anal. Calc. for C18H15N5S.
1-Phenylethyl-3-(3-cyano-1-phenyl-1H-pyrazol-4-yl)thiourea 36
Yield 55%; m.p. 161–164 C (cyclohexane/EtOAc). 1H NMR (DMSO-
d6) 2.88 (t, 2H, CH2, J¼7.5 Hz), 3.69–3.70 (m, 2H, CH2), 7.23–7.34
(m, 5H, ar), 7.46 (t, 1H, ar, J¼ 7.0 Hz), 7.58 (t, 2H, ar, J¼ 7.7 Hz),
7.89 (d, 2H, ar, J¼ 7.7 Hz), 8.09 (br s, 1H, NH), 8.91 (s, 1H, pyrazole
proton), 9.50 (s, 1H, NH). Anal. Calc. for C19H17N5S.
1-(3-Cyano-1-phenyl-1H-pyrazol-4-yl)-3-phenylpropylthiourea 37
Yield 57%; m.p. 133–136 C (cyclohexane/EtOAc). 1H NMR (DMSO-
d6) 1.82–1.90 (m, 2H, CH2), 2.63 (t, 2H, CH2, J¼ 7.3 Hz), 3.49–3.50
(m, 2H, CH2), 7.17–7.31 (m, 5H, ar), 7.45 (t, 1H, ar, J¼ 7.4 Hz), 7.57
(t, 2H, ar, J¼ 7.8 Hz), 7.88 (d, 2H, ar, J¼ 7.9 Hz), 8.09 (br s, 1H, NH),
8.95 (s, 1H, pyrazole proton), 9.42 (s, 1H, NH). Anal. Calc. for
C20H19N5S.
1-(3-Cyano-1-methyl-1H-pyrazol-4-yl)-3-phenylthiourea 38 Yield
45%; 1H NMR (DMSO-d6) 3.92 (s, 3H, CH3), 7.17 (t, 1H, ar,
J ¼ 7.3 Hz), 7.36 (t, 2H, ar, J¼ 7.8 Hz), 7.48 (d, 2H, ar, J ¼ 7.7 Hz),
7.95 (s, 1H, pyrazole proton), 8.39 (br s, 1H, NH), 12.11 (br s, 1H,
NH).
1-Benzyl-3-(3-cyano-1-methyl-1H-pyrazol-4-yl)thiourea 39 Yield
56%; 1H NMR (DMSO-d6) 3.95 (s, 3H, CH3), 5.84 (br s, 2H, CH2),
7.19–7.39 (m, 5H, ar), 7.70 (s, 1H, pyrazole proton), 8.39 (br s, 1H,
NH), 9.47 (br s, 1H, NH).
1-Benzyl-3-(1-benzyl-3-cyano-1H-pyrazol-4-yl)thiourea 40 Yield
50%; 1H NMR (DMSO-d6) 4.71 (d, 2H, CH2, J ¼ 4.5 Hz), 5.40 (s, 2H,
CH2), 7.26–7.40 (m, 10H, ar), 8.44 (br s, 1H, NH); 8.51 (s, 1H, pyra-
zole proton), 9.47 (s, 1H, NH).
1-(3-Cyano-1-phenyl-1H-pyrazol-4-yl)-3-(4-methoxyphenylethyl)th-
iourea 41 Yield 62%; m.p. 260–262 C (cyclohexane/EtOAc). 1H
NMR (DMSO-d6) 2.81 (t, 2H, CH2, J¼7.2 Hz), 3.65–3.67 (m, 2H, CH2),
3.72 (s, 3H, CH3), 6.88 (d, 2H, ar, J¼ 8.9 Hz), 7.17 (d, 2H, ar,
J¼ 8.9 Hz), 7.46 (t, 1H, ar, J¼ 7.0 Hz), 7.58 (t, 2H, ar, J¼ 7.7 Hz), 7.87
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(d, 2H, ar, J¼ 7.7 Hz), 8.05 (br s, 1H, NH), 8.91 (s, 1H, pyrazole pro-
ton), 9.48 (s, 1H, NH). Anal. Calc. for C20H19N5OS.
1-(3-Cyano-1-phenyl-1H-pyrazol-4-yl)-3-[2-(3,4-dimethoxyphenyl)e-
thyl]thiourea 42 Yield 55%; 1H NMR (DMSO-d6) 2.81 (t, 2H, CH2,
J¼ 7.2 Hz), 3.69–3.72 (m, 5H, OCH3þCH2), 3.75 (s, 3H, OCH3), 6.76
(d, 1H, ar, J¼ 8.1 Hz), 6.84 (s, 1H, ar), 6.89 (d, 1H, ar, J¼ 8.2 Hz),
7.46 (t, 1H, ar, J¼ 7.2 Hz), 7.58 (t, 2H, ar, J¼ 7.1 Hz), 7.86 (d, 2H, ar,
J¼ 8.0 Hz), 8.04 (br s, 1H, NH), 8.91 (s, 1H, pyrazole proton), 9.48
(br s, 1H, NH). Anal. Calc. for C21H21N5O2S.
General procedure for the synthesis of S-methylisothiourea deriva-
tives 43–53
A mixture of the suitable thiourea derivatives 32–42 (0.92mmol)
and iodomethane (3.69mmol) in 0.1 N NaOH solution (11.8mL)
was stirred at room temperature until the disappearance of the
starting material (12–24 h). Then, glacial acetic acid was added
until pH 6. The solid which precipitated was collected by filtration
and dried, except compounds 46 and 51 which were isolated
from the reaction mixture by extraction with EtOAc (30mL 3).
Evaporation of the anhydrified (Na2SO4) organic phase gave a
solid which was collected by filtration. These S-methylisothiourea
derivatives were unstable upon recrystallization, thus they were
used for the next step without further purification. It was
observed that derivatives 43–45 and 51 exist in two tautomeric
forms in DMSO solution. In fact, in their 1H NMR spectra there
are two signals assignable to the SCH3 and to the pyrazole pro-
ton. Compounds 44 and 51 also display, two signals assignable
to the OCH3 and SCH3 substituents, respectively (see below for
details).
N-(3-Cyano-1-phenylpyrazolo-4-yl)-N0-phenyl-S-methylisothiourea
43 Yield 86%; 1H NMR (DMSO-d6) mixture of two tautomers (ratio
about 1:2.7) 2.35 (s, SCH3), 2.38 (s, SCH3), 7.30–7.31 (m, ar),
7.42–7.60 (m, ar þ2 NH), 7.98 (d, ar, J¼ 8.0 Hz), 8.89 (s, pyrazole
proton), 8.93 (s, pyrazole proton).
N-(3-Cyano-1-phenylpyrazolo-4-yl)-N0-4-methoxyphenyl-S-methyli-
sothiourea 44 Yield 98%; 1H NMR (DMSO-d6) mixture of two tauto-
mers (ratio about 1:3.2) 2.41 (s, SCH3), 2.43 (s, SCH3), 3.86
(s, OCH3), 3.88 (s, OCH3), 7.41–7.72 (m, ar), 7.96–8.01 (m, ar), 8.93
(s, pyrazole proton), 9.01 (br s, pyrazole protonþNH).
N0-2,4-Dichlorophenyl-N-(3-cyano-1-phenylpyrazolo-4-yl)-S-methyli-
sothiourea 45 Yield 95%; 1H NMR (DMSO-d6) mixture of two tauto-
mers (ratio about 1:3.6) 2.36 (s, SCH3), 2.42 (s, SCH3), 7.09–7.70 (m,
ar), 8.00–8.16 (m, arþNH), 9.00 (s, pyrazole proton), 9.18 (s, pyra-
zole proton).
N0-Benzyl-N-(3-cyano-1-phenylpyrazolo-4-yl)-S-methylisothiourea
46 Yield 98%; 1H NMR (DMSO-d6) 2.48 (s, 3H, SCH3), 5.47 (br s, 2H,
CH2) 7.24–7.34 (m, 5H, ar), 7.44 (t, 1H, ar, J¼ 7.3 Hz), 7.57 (t, 2H, ar,
J¼ 7.6 Hz), 7.97 (d, 2H, ar, J¼ 8.0 Hz), 8.13 (br s, 1H, NH), 8.80 (s,
1H, pyrazole proton).
N-(3-Cyano-1-phenylpyrazolo-4-yl)-N0-phenylethyl-S-methyliso-
thiourea 47 Yield 86%; 1H NMR (DMSO-d6) 2.56 (s, 3H, CH3), 3.04
(t, 2H, CH2, J¼ 7.1 Hz), 4.33 (t, 2H, CH2, J¼ 7.1 Hz), 7.25–7.41 (m,
5H, ar), 7.43 (t, 1H, ar, J¼ 9.2 Hz), 7.57 (t, 2H, ar, J¼ 9.2 Hz), 7.98
(d, 2H, ar, J¼ 9.2 Hz), 8.14 (s, 1H, NH), 8.86 (s, 1H, pyrazole
proton).
N-(3-Cyano-1-phenylpyrazolo-4-yl)-N0-phenylpropyl-S-methyliso-
thiourea 48 Yield 86%; 1H NMR (DMSO-d6) 2.03–2.05 (m, 2H, CH2),
2.51 (s, 3H, CH3), 2.71 (t, 2H, CH2, J¼ 7.4 Hz), 4.16 (t, 2H, CH2,
J¼ 7.4 Hz), 7.21 (t, 1H, ar, J¼ 9.0 Hz), 7.27–7.32 (m, 4H, ar), 7.42 (t,
1H, ar, J¼ 9.0 Hz), 7.56 (t, 2H, ar, J¼ 9.0 Hz), 7.96 (d, 2H, ar,
J¼ 9.0 Hz), 8.03 (s, 1H, NH), 8.83 (s, 1H, pyrazole proton).
N-(3-Cyano-1-methylpyrazolo-4yl)-N0-phenyl-S-methylisothiourea
49 Yield 87%; 1H NMR (DMSO-d6) 2.23 (s, 3H, SCH3), 3.39 (s, 3H,
CH3), 7.33–7.35 (m, 2H, ar), 7.52–7.60 (m, 3H, ar), 8.07 (s, 1H, pyra-
zole proton).
N0-Benzyl-N-(3-cyano-1-methylpyrazolo-4-yl)-S-methylisothiourea
50 Yield 84%; 1H NMR (DMSO-d6) 2.43 (s, 3H, SCH3), 3.99 (s, 3H,
CH3), 5.42 (br s, 2H, CH2), 7.20–7.30 (m, 5H, ar), 7.75 (s, 1H, NH),
8.05 (s, 1H, pyrazole proton).
N0-Benzyl-N-(3-cyano-1-benzylpyrazolo-4-yl)-S-methylisothiourea
51 Yield 81%; 1H NMR (DMSO-d6) mixture of two tautomers (ratio
about 1:6) 2.40 (s, SCH3) 2.43 (s, SCH3), 5.41 (br s, CH2), 5.48 (s,
CH2), 7.14–7.39 (m, ar), 7.81 (br s, NH), 8.25 (s, pyrazole proton),
8.17 (s, pyrazole proton).
N0-4-Methoxyphenylethyl-N-(3-cyano-1-phenylpyrazolo-4-yl)-S-
methylisothiourea 52 Yield 86%; 1H NMR (DMSO-d6) 2.56 (s, 3H,
SCH3), 2.97 (t, 2H, CH2, J¼ 7.3 Hz), 3.75 (s, 3H, OCH3), 4.29 (t, 2H,
CH2, J¼ 7.3 Hz), 6.91 (d, 2H, ar, J¼ 9.5 Hz), 7.24 (d, 2H, ar,
J¼ 9.5 Hz), 7.43 (t, 1H, ar, J¼ 9.5 Hz), 7.57 (t, 2H, ar, J¼ 9.3 Hz), 7.98
(d, 2H, ar, J¼ 9.3 Hz), 8.11 (s, 1H, NH), 8.85 (s, 1H, pyrazole proton).
N0-3,4-Dimethoxyphenylethyl-N-(3-cyano-1-phenylpyrazolo-4-yl)-S-
methylisothiourea 53 Yield 73%; 1H NMR (DMSO-d6) 2.58 (s, 3H,
SCH3), 2.98 (t, 2H, CH2, J¼ 8.5 Hz), 3.73 (s, 3H, OCH3), 3.76 (s, 3H,
OCH3), 4.34 (t, 2H, CH2, J¼ 7.2 Hz), 6.83–6.93 (m, 4H, 3 arþNH),
7.45 (t, 1H, ar, J¼ 7.3 Hz), 7.59 (t, 2H, ar, J¼ 7.8 Hz), 7.99 (d, 2H, ar,
J¼ 8.3 Hz), 8.95 (s, 1H, pyrazole proton).
General procedure for the synthesis of 5-aryl(alkyl)amino-7-amino-
2H-pyrazolo[4,3-d]pyrimidine derivatives 1–3, 5–12
A mixture of the suitable S-methylisothioureas 43–53 (1mmol)
and NH4Cl (20mmol) in formamide (2mL) was microwave irradi-
ated at 110 C for 20min (compounds 9, 10), at 130 C for
40min (compound 12) and for 2 h (compounds 2, 3), at 150 C
for 15min (compounds 1, 5, 8) and for 20min (compounds 6, 7,
11). The suspension was then treated with NaHCO3 saturated
solution until pH 7 and the obtained solid was collected by filtra-
tion to give compounds 1–3. To isolate derivatives 5–12, the
mixture was extracted with CHCl3 (15mL 3), the organic phase
was washed with water (15mL 2) and anhydrified (Na2SO4).
Evaporation of the solvent at reduced pressure afforded a resi-
due which was taken up with diethyl ether (2–3mL) and col-
lected by filtration. The crude derivatives were purified by
recrystallization, except compounds 1, 6, 7, 10, 11 which were
first purified by column chromatography or preparative TLC (see
below for details).
7-Amino-5-phenylamino-2-phenyl-2H-pyrazolo[4,3-d]pyrimidine 1
Purified by column chromatography (Et2O/cyclohexane/EtOAc
3:1:1). Yield 66%; m.p. 252–254 C (EtOH). 1H NMR (DMSO-d6) 6.86
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(t, 1H, ar, J¼ 7.3 Hz), 7.23 (t, 2H, ar, J¼ 7.6 Hz), 7.41–7.45 (m, 3H,
1 arþNH2), 7.58 (t, 2H, ar, J¼ 7.6 Hz), 7.90 (d, 2H, ar, J¼ 8.5 Hz),
8.03 (d, 2H, ar, J¼ 8.5 Hz), 8.74 (s, 1H, H-3), 8.76 (br s, 1H, NH).
Anal. Calc. for C17H14N6.
7-Amino-5-(4-methoxyphenyl)amino-2-phenyl-2H-pyrazolo[4,3-
d]pyrimidine 2 Yield 62%; m.p. 253–255 C (cyclohexane/EtOAc);
1H NMR (DMSO-d6) 3.82 (s, 3H, OCH3), 6.84 (d¸ 2H, ar, J¼ 8.9 Hz),
7.45–7.40 (m, 3H, 1 arþNH2), 7.58 (t, 2H, ar, J¼ 7.7 Hz), 7.75 (d, 2H,
J¼ 8.9 Hz), 8.02 (d, 2H, ar, J¼ 8.2 Hz), 8.57 (s, 1H, NH), 8.68 (s, 1H,
H-3). Anal. Calc. for C18H16N6O.
7-Amino-5–(2,4-dichlorophenyl)amino-2-phenyl-2H-pyrazolo[4,3-
d]pyrimidine 3 Yield 58%; m.p. 251–252 C (cyclohexane/EtOAc);
1H NMR (DMSO-d6) 7.40–7.48 (m, 3H, 2 arþNH), 7.54 (s, 1H, ar),
7.53–7.61 (m, 2H, ar), 7.61–7.79 (br s, 2H, NH2), 8.02 (d, 2H,
J¼ 7.9 Hz), 8.67 (d, 1H, J¼ 8.9 Hz), 8.82 (s, 1H, H-3). Anal. Calc. for
C17H12Cl2N6.
7-Amino-5-benzylamino-2-phenyl-2H-pyrazolo[4,3-d]pyrimidine 5
Purified by preparative TLC (Et2O/cyclohexane/EtOAc 3:1:1). Yield
60%; m.p. 143–145 C (cyclohexane/EtOAc). 1H NMR (DMSO-d6)
4.49 (d, 2H, CH2, J¼ 6.3 Hz), 6.71 (t, 1H, NH, J¼ 6.3 Hz), 7.18 (t, 1H,
ar, J¼ 7.1 Hz), 7.26–7.34 (m, 6H, 4 arþNH2), 7.39 (t, 1H, ar,
J¼ 7.4 Hz), 7.55 (t, 2H, ar, J¼ 7.5 Hz), 7.95 (d, 2H, ar, J¼ 7.6 Hz),
8.48 (s, 1H, H-3). Anal. Calc. for C18H16N6.
7-Amino-5-(2-phenylethyl)amino-2-phenyl-2H-pyrazolo[4,3-d]pyr-
imidine 6 Purified by column chromatography (cyclohexane/
EtOAc/MeOH 6:4:1). Yield 65%; m.p. 168–171 C (cyclohexane/
EtOAc). 1H NMR (DMSO-d6) 2.86 (t, 2H, CH2, J¼ 7.1 Hz), 3.45–3.50
(m, 2H, CH2), 6.12 (br s, 1H, NH), 7.18–7.32 (m, 7H, 5 arþNH2), 7.39
(t, 1H, ar, J¼ 7.5 Hz), 7.56 (t, 2H, ar, J¼ 7.5 Hz), 7.98 (d, 2H, ar,
J¼ 7.7 Hz), 8.52 (s, 1H, H-3). Anal. Calc. for C19H18N6.
7-Amino-5-(3-phenylpropyl)-2-phenyl-2H-pyrazolo[4,3-d]pyrimi-
dines 7 Purified by column chromatography (eluent cyclohexane/
EtOAc/MeOH 6:4:1). Yield 58%; m.p. 159–162 C (EtOAc). 1H NMR
(DMSO-d6) 1.83–1.86 (m, 2H, CH2), 2.64 (t, 2H, CH2, J¼ 7.4 Hz), 3.27
(m, 2H, CH2), 6.20 (br s, 1H, NH), 7.19–7.30 (m, 7H, 5 arþNH2), 7.40
(t, 1H, ar, J¼ 9.0 Hz), 7.56 (t, 2H, ar, J¼ 7.6 Hz), 7.97 (d, 2H, ar,
J¼ 7.9 Hz), 8.50 (s, 1H, H-3). Anal. Calc. for C20H20N6.
7-Amino-2-methyl-5-phenylamino-2H-pyrazolo[4,3-d]pyrimidine 8
Yield 42%; m.p. 252–254 C (EtOH). 1H NMR (DMSO-d6) 4.05 (s, 3H,
Me), 6.84 (t, 1H, ar, J ¼ 7.2 Hz), 7.19–7.21 (m, 4H, 2 arþNH2), 7.75
(d, 2H, ar, J ¼ 7.2 Hz), 7.87 (s, 1H, H-3), 8.62 (br s, 1H, NH). Anal.
Calc. for C12H12N6.
7-Amino-5-benzylamino-2-methyl-2H-pyrazolo[4,3-d]pyrimidine 9
Yield 80%; m.p. 213–214 C (EtOH); 1H NMR (DMSO-d6) 3.98 (s, 3H,
CH3), 4.45 (d, 2H, CH2, J ¼ 6.4 Hz), 6.47 (br s, 1H, NH), 7.05 (br s,
2H, NH2), 7.16–7.32 (m, 5H, ar), 7.70 (s, 1H, H-3). IR: 3326, 3179,
1658. Anal. Calc. For C13H14N6.
7-Amino-2-benzyl-5-benzylamino-2H-pyrazolo[4,3-d]pyrimidine 10
Yield 40%; m.p. 174–175 C (cyclohexane/EtOAc). 1H NMR (DMSO-
d6) 4.45 (d, 2H, CH2, J¼ 6.3 Hz), 5.45 (s, 2H, CH2), 6.58 (br s, 1H,
NH), 7.11 (br s, 2H, NH2), 7.15–7.36 (m, 10H, ar), 7.87 (s, 1H, H-3).
Anal. Calc. for C19H18N6.
7-Amino-5-[2–(4-methoxyphenyl)ethyl]amino-2-phenyl-2H-pyra-
zolo[4,3-d]pyrimidine 11 Purified by column chromatography
(cyclohexane/EtOAc/MeOH 6:4:1), Yield 58%; m.p. 142–145 C
(cyclohexane/EtOAc). 1H NMR (DMSO-d6) 2.73 (t, 2H, CH2,
J¼ 7.3 Hz), 3.38–3.41 (m, 2H, CH2), 3.73 (s, 3H, OCH3), 6.03 (br s,
1H, NH), 6.69 (d, 2H, ar, J¼ 8.9 Hz), 7.04 (d, 2H, ar, J¼ 8.9 Hz), 7.22
(br s, 2H, NH2), 7.41 (t, 1H, ar, J¼ 7.3 Hz), 7.57 (t, 2H, ar, J¼ 7.6 Hz),
7.98 (d, 2H, ar, J¼ 7.9 Hz), 8.51 (s, 1H, H-3). Anal. Calc. for
C20H20N6O.
7-Amino-5-[2-(3,4-dimethoxyphenyl)ethyl]amino-2-phenyl-2H-pyra-
zolo[4,3-d]pyrimidine 12 Purified by preparative TLC (cyclohexane/
EtOAc/MeOH 6:4:1). Yield 45%; m.p. 100–102 C (H2O/MeOH).
1H
NMR (DMSO-d6) 2.79 (t, 2H, CH2, J¼ 7.2 Hz), 3.43–3.48 (m, 2H,
CH2), 3.72 (s, 3H, OCH3), 3.74 (s, 3H, OCH3), 6.10 (br s, 1H, NH),
6.75 (d, 1H, ar, J¼ 6.5 Hz), 6.84–6.87 (m, 2H, ar), 7.27 (br s, 2H,
NH2), 7.39 (t, 1H, ar, J¼ 7.2 Hz), 7.56 (t, 2H, ar, J¼ 7.7 Hz), 7.97 (d,
2H, ar, J¼ 7.8 Hz), 8.51 (s, 1H, H-3). Anal. Calc. for C21H22N6O2.
General procedure for the synthesis of the pyrazolo[4,3-d]pyrimi-
dine-7-amine derivatives 4, 13 and 14
To a suspension of the methoxy-substituted pyrazolopyrimidine
derivatives 2, 11 and 12 (1.02mmol) in anhydrous CH2Cl2 (20mL),
a 1 M BBr3 solution (2.60mL for 2, 11 and 5.2mL for 12) in CH2Cl2
was added at 0 C, under nitrogen atmosphere. The mixture was
stirred at room temperature for 20–24 h (compounds 4, 13) or
16 h (compound 14), then was diluted with water (10mL) and
neutralized with NaHCO3 saturated solution. The organic solvent
was removed under reduced pressure and the obtained precipi-
tate was collected by filtration and recrystallized. The crude deriva-
tive 4 was first purified by column chromatography (eluent CHCl3/
MeOH 9:1) and then recrystallized.
7-Amino-5-(4-hydroxyphenyl)amino-2-phenyl-2H-pyrazolo[4,3-
d]pyrimidine 4 Yield 67%; m.p. 223–225 C (EtOAc/cyclohexane);
1H NMR (DMSO-d6) 6.65 (d, 2H, ar, J¼ 8.8 Hz), 7.30–7.45 (m, 3H,
2 arþNH2), 7.57 (t, 2H, ar, J¼ 7.6 Hz), 7.63 (d, 2H, ar, J¼ 8.8 Hz),
8.01 (d, 2H, ar, J¼ 8.3 Hz), 8.41 (s, 1H, NH), 8.65 (s, 1H, H-3), 8.85 (s,
1H, OH). Anal. Calc. for C17H14N6O.
7-Amino-5-(4-hydroxyphenethyl)amino-2-phenyl-2H-pyrazolo[4,3-
d]pyrimidine 13 Yield 89%; m.p. 241–244 C (EtOAc/EtOH). 1H NMR
(DMSO-d6) 2.73 (t, 2H, CH2, J¼ 7.3 Hz), 3.38–3.40 (m, 2H, CH2), 6.03
(br s, 1H, NH), 6.68 (d, 2H, ar, J¼ 8.3 Hz), 7.04 (d, 2H, ar, J¼ 8.3 Hz),
7.22 (br s, 2H, NH2), 7.41 (t, 1H, ar, J¼ 7.4 Hz), 7.56 (t, 2H, ar,
J¼ 7.7 Hz), 7.97 (d, 2H, ar, J¼ 7.8 Hz), 8.51 (s, 1H, H-3), 9.14 (s, 1H,
OH). Anal. Calc. for C19H18N6O.
7-Amino-5-(3,4-dihydroxyphenethyl)amino-2-phenyl-2H-pyra-
zolo[4,3-d]pyrimidine 14 Yield 50%; m.p. 242–243 C (EtOH). 1H
NMR (DMSO-d6) 2.65 (t, 2H, CH2, J¼ 7.1 Hz), 3.37–3.41 (m, 2H,
CH2), 6.03 (t, 1H, NH, J¼ 5.8 Hz), 6.59–6.47 (d, 1H, ar, J¼ 8.0 Hz),
6.63–6.66 (m, 2H, ar), 7.23 (br s, 2H, NH2), 7.40 (t, 1H, ar,
J¼ 7.4 Hz), 7.56 (t, 2H, ar, J¼ 7.6 Hz), 7.97 (d, 2H, ar, J¼ 7.7 Hz),
8.51 (s, 1H, H-3), 8.62 (br s, 1H, OH), 8.74 (br s, 1H, OH). Anal. Calc.
for C19H18N6O2.
Synthesis of 5,7-dichloro-2-phenyl-2H-pyrazolo[4,3-d]pyrimidine 55
A suspension of the pyrazolopyrimidine-5,7-dione derivative 5420
(2mmol) and N,N-dimethylaniline (3.95mmol) in phosphorus
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oxychloride (5mL) was microwave irradiated at 150 C for 20min.
The excess of phosphorus oxychloride was distilled off under
reduced pressure and the residue was treated with water (about
5 10mL). The crude product was collected by filtration and
recrystallized. Yield 96%; m.p. 252–254 C (EtOH). 1H NMR (DMSO-
d6) 7.62 (t, 1H, ar, J¼ 9.1 Hz), 7.69 (t, 2H, ar, J¼ 9.3 Hz), 8.17 (d, 2H,
ar, J¼ 9.1 Hz), 9.69 (s, 1H, H-3). Anal. Calc. for C11H6N4Cl2.
Synthesis of 7-amino-5-chloro-2-phenyl-2H-pyrazolo[4,3-d]pyrimi-
dine 56
A suspension of the suitable 5,7-dichloropyrazolopyrimidine
derivative 55 (1.72mmol) in aqueous 33% ammonia solution
(10mL) was microwave irradiated at 100 C for 30min. The sus-
pension was cooled at room temperature and the solid was col-
lected by filtration and recrystallized. Yield 90%; m.p. 260–261 C
(2-ethoxyethanol). 1H NMR (DMSO-d6) 7.50 (t, 1H, ar, J¼ 8.0 Hz),
7.62 (t, 2H, ar, J¼ 8.0 Hz), 8.05 (d, 2H, ar, J¼ 8.0 Hz), 8.35 (br s,
1H, NH2), 8.38 (br s, 1H, NH2), 9.05 (s, 1H, H-3). Anal. Calc. for
C11H8ClN5.
General procedure for the synthesis of 5-(4-R-piperazin-1-yl)-substi-
tuted pyrazolo[4,3-d]pyrimidines 15–21
A mixture of the 5-chloro-pyrazolopyrimidine derivative 56
(0.41mmol), the suitable N-substituted piperazine 57–63
(0.82mmol) and ethyldiisopropylamine (0.49mmol) in N-methyl-
pyrrolidone (2mL) was heated by microwave irradiation in the
conditions described below for each compound. The obtained
slurry was poured dropwise into water (50mL) under vigorous stir-
ring. The solid which precipitated was collected by filtration, puri-
fied by chromatography (column or preparative TLC, as reported
below for each derivative) and then recrystallized, except deriva-
tive 16 which was directly recrystallized.
The not commercially available 1-substituted piperazines were
prepared as reported below (60) or as previously described (59,
61)35,36.
7-Amino-2-phenyl-5-(4-phenylpiperazin-1-yl)-2H-pyrazolo[4,3-d]pyr-
imidine 15 The reaction mixture was microwave irradiated at
150 C for 15min. Column chromatography, eluent: acetonitrile.
Yield 48%; m.p. 183–185 C (cyclohexane/EtOAc). 1H NMR (DMSO-
d6) 3.18–3.20 (m, 4H, piperazine protons), 3.80–3.85 (m, 4H, pipera-
zine protons), 6.80 (t, 1H, ar, J¼ 7.1 Hz), 7.00 (d, 2H, ar, J¼ 7.3 Hz),
7.24 (t, 2H, ar, J¼ 7.3 Hz), 7.40–7.46 (m, 3H, 1 ar, þNH2), 7.57 (t, 2H,
ar, J¼ 7.5 Hz), 8.00 (d, 2H, ar, J¼ 8.4 Hz), 8.59 (s, 1H, H-3). Anal.
Calc. for C21H21N7.
7-Amino-5-(4-benzylpiperazin-1-yl)-2-phenyl-2H-pyrazolo[4,3-d]pyr-
imidine 16 The reaction mixture was microwave irradiated at
130 C for 25min. Yield 74%; m.p. 201–202 C (diisopropyl ether/
MeOH). 1H NMR (DMSO-d6) 2.39–2.42 (m, 4H, piperazine protons),
3.50 (s, 2H, CH2), 3.67–3.71 (m, 4H, piperazine protons), 7.24–7.29
(m, 1H, ar), 7.33–7.35 (m, 4H, ar), 7.39–7.42 (m, 3H, 1 arþNH2),
7.56 (t, 2H, ar, J¼ 7.6 Hz), 7.97 (d, 2H, ar, J¼ 7.7 Hz), 8.55 (s, 1H, H-
3). Anal. Calc. for C22H23N7.
7-Amino-5-(4-phenylethylpiperazin-1-yl)-2-phenyl-2H-pyrazolo[4,3-
d]pyrimidine 17 The reaction mixture was microwave irradiated at
150 C for 1 h. Column chromatography: eluent EtOAc/CH2Cl2/
MeOH, 8:3:1. Yield 65%; m.p. 198–200 C (cyclohexane/EtOAc). 1H
NMR (DMSO-d6) 2.63–2.70 (m, 6H, 4 piperazine protonsþCH2),
2.87–2.91 (m, 2H, CH2), 3.88–3.90 (m, 4H, piperazine protons), 5.53
(br s, 2H, NH2), 7.23–7.34 (m, 5H, ar), 7.41 (t, 1H, ar, J¼ 7.4 Hz),
7.53 (t, 2H, ar, J¼ 8.2 Hz), 7.81 (d, 2H, ar, J¼ 7.6 Hz), 8.08 (s, 1H, H-
3). Anal. Calc. for C23H25N7.
7-Amino-5-(4-(2,4,6-trifluoro)benzylpiperazin-1-yl)-2-phenyl-2H-pyr-
azolo[4,3-d]pyrimidine 18 The reaction mixture was microwave
irradiated at 150 C for 1 h and 45min. Column chromatography:
eluent cyclohexane/EtOAc 7:3. Yield 85%; m.p. 233–235 C (cyclo-
hexane/EtOAc). 1H NMR (DMSO-d6) 2.43 (br s, 4H, piperazine pro-
tons), 3.57 (s, 2H, CH2), 3.67 (br s, 4H, piperazine protons), 7.20 (t,
1H, ar, J¼ 8.3 Hz), 7.41 (t, 2H, ar, J¼ 7.2 Hz), 7.50 (br s, 2H, NH2),
7.56 (t, 2H, ar, J¼ 7.7 Hz), 7.97 (d, 2H, ar, J¼ 8.0 Hz), 8.55 (s, 1H, H-
3). Anal. Calc. for C22H20N7F3.
7-Amino-5-(4-(2-chloro-4-fluoro)benzylpiperazin-1-yl)-2-phenyl-2H-
pyrazolo[4,3-d]pyrimidine 19 The reaction mixture was microwave
irradiated at 150 C for 1 h and 15min. Column chromatography:
eluent cyclohexane/EtOAc 7:3. Yield 53%; m.p. 203–205 C. 1H
NMR (DMSO-d6) 2.47 (br s, 4H, piperazine protons), 3.57 (s, 2H,
CH2), 3.70 (br s, 4H, piperazine protons), 7.24 (t, 1H, ar, J¼ 6.2 Hz),
7.41–7.60 (m, 7H, arþNH2), 7.98 (d, 2H, ar, J¼ 7.8 Hz), 8.56 (s, 1H,
H-3). Anal. Calc. for C22H21N7ClF.
7-Amino-2-phenyl-5-[(4-(2-furoyl)piperazin-1-yl]-2H-pyrazolo[4,3-
d]pyrimidine 20 The reaction mixture was microwave irradiated
at 150 C for 1 h. Preparative TLC: eluent cyclohexane/EtOAc/
MeOH 3:6:1. Yield 84%; m.p. 263–264 C (EtOH). 1H NMR (DMSO-
d6) 3.74–3.79 (m, 8H, CH2), 6.65–6.66 (m, 1H, furan proton),
7.03–7.04 (m, 1H, furan proton), 7.42 (t, 1H, ar, J¼ 7.4 Hz), 7.51
(br s, 2H, NH2), 7.57 (t, 2H, ar, J¼ 7.8 Hz), 7.87 (m, 1H, furan
proton), 7.99 (d, 2H, ar, J¼ 7.6 Hz), 8.60 (s, 1H, H-3). Anal. Calc.
for C20H19N7O2.
Tert-butyl 4-(7-amino-2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-5-yl)pi-
perazine 1-carboxylate 21 The reaction mixture was microwave
irradiated at 150 C for 1 h and 30min. Column chromatography:
eluent cyclohexane/EtOAc 6:4. Yield 76%; m.p. 169–171 C. 1H
NMR (DMSO-d6) 1.43 (s, 9H, t-But), 3.34–3.38 (m, 4H, piperazine
protons), 3.63–3.68 (m, 4H, piperazine protons), 7.42 (t, 1H, ar,
J¼ 7.3 Hz), 7.50 (br s, 2H, NH2), 7.57 (t, 2H, ar, J¼ 7.8 Hz), 7.99
(d, 2H, ar, J¼ 8.2 Hz), 8.59 (s, 1H, H-3). Anal. Calc. for
C20H25N7O2.
Synthesis of 2-phenyl-5-(4-(methyl-2-furyl)piperazin-1-yl)-2H-pyra-
zolo[4,3-d]pyrimidin-7-amine 22
A solution of the 5-(4-(2-furoyl)piperazin-1-yl) derivative 20
(1mmol) in anhydrous THF (5mL) was added to a suspension of
LiAlH4 (3mmol) in anhydrous THF (20mL) at 0 C. The suspension
was stirred for 16 h at room temperature, then treated with water
(10mL) and the solid which precipitated was filtered off. The clear
solution was diluted with water (about 30mL) and extracted with
EtOAc (3 20mL). The organic phase was anhydrified and the
solvent removed at reduced pressure to give a solid which was
purified by preparative TLC (eluent: cyclohexane/EtOAc/MeOH
5:5:0.4). Yield 65%; m.p. 199–200 C. 1H NMR (DMSO-d6) 2.40–2.43
(m, 4H, piperazine protons), 3.53 (s, 2H, CH2), 3.67–3.69 (m, 4H,
piperazine protons), 6.30–6.32 (m, 1H, furan proton), 6.41–6.43 (m,
1H, furan proton), 7.38–7.43 (m, 3H, 1 arþNH2), 7.56–7.70 (m, 3H,
2 ar þ1 furan proton), 7.98 (d, 2H, ar, J¼ 7.4 Hz), 8.54 (s, 1H, H-3).
Anal. Calc. for C20H21N7O.
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Synthesis of 1-(2,4,6-trifluorobenzyl)piperazinium trifluoroacetate
60
A solution of N-(Boc)piperazine 63 (2.06mmol) and 2,4,6-trifluoro-
benzaldehyde (1.87mmol) in anhydrous CH2Cl2 (20mL) was stirred
at room temperature for 1.5 h, then triacetoxy sodium borohydride
(7.47mmol) was added portion wise. The mixture was refluxed for
48 h, then treated with iced water (10mL) and diluted with CH2Cl2
(15mL). The aqueous phase was extracted with CH2Cl2 (10mL 3)
and the organic phases were collected and anhydrified (Na2SO4).
Evaporation of the solvent at reduced pressure gave the crude
tert-butyl-4–(2,4,6-trifluorobenzyl)piperazine-1-carboxylate which
was purified by preparative TLC (eluent: CH2Cl2/acetonitrile/cyclo-
hexane, 9:1:1) and obtained as a yellow oil. Yield 91%; 1H NMR
(CDCl3) 1.46 (s, 9H, t-But), 2.41–2.45 (m, 4H, piperazine protons),
3.42–3.46 (m, 4H, piperazine protons), 3.67 (s, 2H, CH2), 6.69 (t, 2H,
ar, J ¼ 7.8 Hz).
This derivative was then transformed into the title compound
as follows. A solution of concentrated trifluoroacetic acid (2.5mL)
in anhydrous CH2Cl2 (2.5mL) was added dropwise to a solution of
tert-butyl-4–(2,4,6-trifluorobenzyl)piperazine-1-carboxylate
(1.04mmol) in anhydrous CH2Cl2 (20mL). The solution was stirred
at room temperature for 3 h, then the solvent and the excess of
the acid were removed at reduced pressure. The residue was
treated with Et2O (5mL) to give a solid which was collected by fil-
tration and dried. The crude compound was used for the next
step without further purification. Yield 67%; 1H NMR (CDCl3)
2.29–3.31 (m, 4H, piperazine protons), 3.49–3.52 (m, 4H, piperazine
protons), 4.12 (s, 2H, CH2), 6.73 (t, ar, J¼ 7.8 Hz).
Synthesis of 4-(7-amino-2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-5-
yl)piperazin-1-ium trifluoroacetate 64
The title compound was obtained by treatment of compound
21 (1.04mmol) with trifluoroacetic acid, in the conditions
described previously to prepare compound 60 from the corre-
sponding N-Boc-derivative. The crude compound was used dir-
ectly for the next step without purification. Yield 68%; 1H NMR
(DMSO-d6) 3.22–3.29 (m, 4H, piperazine protons), 3.98–4.02 (m,
4H, piperazine protons), 7.51 (t, 1H, ar, J¼ 7.3 Hz), 7.63 (t, 2H,
ar, J¼ 7.8 Hz), 8.03 (d, 2H, ar, J¼ 8.2 Hz), 8.69 (s, 1H, H-3), 9.25
(br s, 2H, NH2
þ).
General procedure for the synthesis of 5–(4-acylpiperazin-1-yl)sub-
stituted-2H-pyrazolo[4,3-d]pyrimidin-7-amines 23 and 24
A mixture of derivative 64 (0.98mmol) and triethylamine
(1.96mmol) in anhydrous THF (20ml) was stirred at room tempera-
ture for 1 h. Then, 3,3-dimethylbutiryl chloride (1.17mmol) or phe-
nylacetyl chloride (1.17mmol) was added and the solution was
stirred at room temperature for 5 h or 3 h, respectively. The mix-
ture was diluted with water (15ml) and extracted with EtOAc
(20 3ml). The organic phase was anhydrified (Na2SO4) and the
solvent evaporated at reduced pressure to give a solid which was
taken up with cyclohexane and EtOAc, collected by filtration and
purified by column chromatography (eluent CHCl3/MeOH 10:0.5
for compound 23, MeOH for derivative 24).
7-Amino-2-phenyl-5-(4-(3,3-dimethylbutiryl)piperazin-1-yl)-2H-pyra-
zolo[4,3-d]pyrimidine 23 Yield 32%; m.p. 178–180 C. 1H NMR
(DMSO-d6) 1.02 (s, 9H, t-But), 2.29 (s, 2H, CH2), 3.58–3.60 (m, 4H,
piperazine protons), 3.69–3.72 (m, 4H, piperazine protons),
7.42–7.46 (m, 3H, 1 arþNH2) 7.59 (t, 2H, ar, J¼ 7.4 Hz), 8.00 (d, 2H,
ar, J¼ 7.9 Hz), 8.60 (s, 1H, H-3). Anal. Calc. for C21H27N7O.
7-Amino-2-phenyl-5-(4-phenylacetylpiperazin-1-yl)-2H-pyrazolo[4,3-
d]pyrimidine 24 Yield 69%; m.p. 207–209 C (CH3NO2).
1H NMR
(DMSO-d6) 3.52–3.57 (m, 4H, piperazine protons), 3.60–3.66 (m, 4H,
piperazine protons), 3.77 (s, 2H, CH2), 7.21–7.34 (m, 5H, ar),
7.42–7.50 (m, 3H, 1 arþNH2), 7.57 (t, 2H, ar, J¼ 7.9 Hz), 7.98 (d, 2H,
ar, J¼ 8.2 Hz), 8.59 (s, 1H, H-3). Anal. Calc. for C23H23N7O.
Molecular modeling studies
Software overview
MOE suite (Molecular Operating Environment, version 2015.1001)39
was used to perform most general molecular modeling operations.
Docking simulations were performed using the GOLD (Genetic
Optimization for Ligand Docking, version 5.2) suite40. Quantum
mechanical calculation of PM3 charges was carried out with the
software MOPAC41 as implemented in the MOE suite.
Analyses of docking poses in terms of energy calculation and
visual inspection were executed taking advantage of the MOE
suite.
Molecular modeling studies have been performed on a 8 CPU
(IntelVR XeonVR CPU E5-1620 3.70 GHz) linux workstation.
Three-dimensional structures of adenosine receptors
Among all the available crystallographic structures of hA2A AR co-
crystallized with a ligand in the orthosteric binding site, we opted
for a complex with the antagonist ZM-241385 because of the
structural similarity of its ([1,2,4]triazolo[1,5,a][1,3,5]triazin-5,7-yl)di-
amine scaffold with the (pyrazolo[4,3-d]pyrimidin-5,7-yl)diamine
scaffold of the compounds under investigation. The crystallo-
graphic structure identified with 4EIY PDB code42 was selected
among all the structures co-crystallized with ZM-241385, because
of its highest resolution (1.80 Å).
Since to date there are no crystallographic structures available
for hA3 and hA1 ARs, we retrieved from the Adenosiland web-plat-
form43,44 previously developed by our research group, their hom-
ology models constructed using 4EIY structure as template. Those
models were constructed in the presence of ZM-241385 as envir-
onment for induced fit, so the resulting structures consist in com-
plexes between each AR subtype and the antagonist ZM-241385.
The residues are identified according to the generic Ballesteros
Weinstein numbering system45.
Molecular docking
Three-dimensional structures of ligands were built taking advan-
tage of the MOE-Builder tool and ionization states were predicted
using the MOE-Protonate-3D tool46. Ligand structures were sub-
jected to MMFF94 energy minimization until the root mean
square (rms) gradient fell below 0.05 kcal mol 1Å1. GOLD dock-
ing tool40 was selected as conformational search program and
GoldScore as scoring function, thanks to a docking benchmark
study previously carried out in our laboratory38,47. For each com-
pound, 10 docking runs were performed on each receptor sub-
type, searching in a sphere of 20 Å radius centered on the
coordinates of the center of mass of ZM-241385 in complex with
the receptor. Along with the compounds under investigation,
docking simulations were conducted also for ZM-241385 as a ref-
erence example.
After computing atomic partial charges both of ligand poses,
using PM3/ESP method, and receptors, using Amber10EHT force
field, electrostatic and van der Waals contributions to the binding
energy were calculated with MOE.
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Interaction energy fingerprints (IEFs)
Individual electrostatic and hydrophobic interactions, hereinafter
identified as IEele and IEhyd, respectively, were computed
between ligand poses and each protein residue involved in bind-
ing37,38. Both these contributions were computed using MOE and,
in particular, IEele were calculated as non-bonded electrostatic
interactions energy term of the force field, so they are expressed
in kcal/mol. Instead, IEhyd were computed as contact hydrophobic
surfaces and are associated to an adimensional score (the higher
the better). The data obtained by this analysis were reported in a
graphic, called Interaction Energy Fingerprints (IEFs), representing
residues (x-axis) in the form of equally high rectangles rendered
according to a colorimetric scale. As regards IEele, colors from
blue to red represent energy values ranging from negative to
positive values; for IEhyd, colors from white to dark green depict
scores going from 0 to positive values. More precisely, we
retrieved the coordinates of the center of mass of ZM-241385 in
the structure of each AR subtype complex. Only residues within
10Å from this point were retained as belonging to the binding
site, and plotted in the IEFs.
Interaction Energy Fingerprints comparison (IEFs comparison)
A new method has been introduced to evaluate docking results,
which rests on the observation that ligands able to bind the same
site of a protein often share a similar interaction pattern, too. The
new method consists in the comparison of the IEFs of the pose of
a candidate ligand (hereinafter called “docked”) with the IEFs of a
ligand whose bound conformation is considered known (herein-
after called “reference”).
A quantitative estimation of the similarity of IEFs is computed
as root mean square deviation (RMSD) between per residue inter-
action energies of the docked and the reference poses, both for
electrostatic and hydrophobic interactions. This would inform
about the average divergence of the docked from the reference:
in particular a high RMSD value corresponds to large differences.
So far, there is no information about the direction of the diver-
gence thus, along with RMSD, another analysis, named RMSDtrend,
has been proposed. This consists of the sum of differences
between per residue interaction energies of the docked and the
reference, weighted by the number of residues of the binding site.
A more favorable interaction energy profile would correspond to a
negative RMSDtrend in the case of electrostatic interactions, while
to a positive one in the case of hydrophobic interactions.
In summary, low RMSD values, along with negative electrostatic
RMSDtrend and high hydrophobic RMSDtrend could be interpreted
as an indication of a higher “stability” of the docked pose respect
the reference in the orthosteric binding state.
Moreover, this approach could be expanded to compare the
behavior of the same ligand on different receptor subtypes, in
order to have a preliminary “selectivity” profile based on the
stabilities of the docked poses in their corresponding orthosteric
binding states. In that case, RMSD and RMSDtrend are computed
for a docked compound against a reference on each receptor sub-
type. The reference compound should be a known good binder
for each subtype and, at best, the crystallographic structure of the
complex should be known.
In our case, ZM-241385 was chosen as reference compound,
since it is a ligand for all ARs, having a Ki of 774 nM for hA1 AR, of
1.6 nM for hA2A AR and of 743 nM for hA3 AR
5. As regards the
hA2A receptor, 4EIY crystallographic complex could be employed,
while, for hA1 and hA3 ARs, we used the homology models, that
are receptor-ZM-241385 complexes, since they were constructed
considering ZM-241385 as environment for induced fit.
An additional graph was added, which allows to compare elec-
trostatic and hydrophobic IEFs RMSDs and RMSDtrend for different
ligands on the different AR subtypes. RMSD and RMSDtrend for the
ligands (y-axis) on the various receptors (x-axis) were reported on
a heat map, where they are represented by a colorimetric scale
going from red to blue from unfavorable to favorable values.
Finally, if a ligand presents blue rectangles on all receptors, it is
expected to be “non-selective”, otherwise red and blue rectangles
should describe lower and higher stability values, respectively,
among the different receptor subtypes.
MMsDocking video maker
To facilitate the visualization and analysis of data obtained from
the docking simulations, we have implemented a in-house tool,
named MMsDocking video maker, for the automated production
of a video that shows the most relevant docking data, such as
docking poses, per residue IEhyd and IEele data, experimental
binding data and scoring values. Videos were mounted using
MEncoder48 starting from images obtained with the following pro-
cedure: the heat maps in the background were drawn with
GNUPLOT 4.649 starting from per residue IEhyd and IEele data
computed with MOE. 2d depictions of compounds were generated
using the open-source cheminformatics toolkit RDKit50.
Representations of docking poses within the binding site were
constructed using CHIMERA51.
Pharmacological assays
Human cloned A1, A2A and A3 AR binding assay
All synthesized compounds were tested to evaluate their affinity
at human A1, A2A and A3 ARs. Displacement experiments of
[3H]DPCPX (1 nM) to hA1 CHO membranes (50 mg of protein/assay)
and at least 6–8 different concentrations of antagonists for
120min at 25 C in 50mM Tris-HCl buffer pH 7.4 were per-
formed52. Non-specific binding was determined in the presence
1 mM of DPCPX (10% of the total binding). Binding of [3H]ZM-
241385 (1 nM) to hA2ACHO membranes (50mg of protein/assay)
was performed by using 50mM Tris-HCl buffer, 10mM MgCl2 pH
7.4 and at least 6–8 different concentrations of antagonists studied
for an incubation time of 60min at 4 C53. Non-specific binding
was determined in the presence of 1mM ZM-241385 and was
about 20% of total binding. Competition binding experiments to
hA3 CHO membranes (50 mg of protein/assay) were performed
incubating 0.5 nM [125I]AB-MECA, 50mM Tris-HCl buffer, 10mM
MgCl2, 1mM EDTA, pH 7.4 and at least 6–8 different concentra-
tions of examined ligands for 60min at 37 C54. Non-specific bind-
ing was defined as binding in the presence of 1mM AB-MECA and
was about 20% of total binding. Bound and free radioactivity were
separated by filtering the assay mixture through Whatman GF/B
glass fiber filters by using a Brandel cell harvester. The filter bound
radioactivity was counted by Scintillation Counter Packard Tri Carb
2810 TR with an efficiency of 58%.
Measurement of cyclic AMP levels in CHO cells transfected with
hA2B AR
CHO cells transfected with hA2B AR subtypes were washed with
phosphate-buffered saline, diluted trypsin and centrifuged for
10min at 200 g. The cells (1 106 cells/assay) were suspended in
0.5ml of incubation mixture (mM): NaCl 15, KCl 0.27, NaH2PO4
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0.037, MgSO4 0.1, CaCl2 0.1, Hepes 0.01, MgCl2 1, glucose 0.5, pH
7.4 at 37 C, 2 IU/ml adenosine deaminase and 4–(3-butoxy-4-
methoxybenzyl)-2-imidazolidinone (Ro 20–1724) as phospho-
diesterase inhibitor and preincubated for 10min in a shaking bath
at 37 C. The potency of antagonists to the A2B AR was determined
by the inhibition of NECA (200 nM)-induced cyclic AMP produc-
tion55. The reaction was terminated by the addition of cold 6% tri-
chloroacetic acid (TCA). The TCA suspension was centrifuged at
2000 g for 10min at 4 C and the supernatant was extracted four
times with water saturated diethyl ether. The final aqueous solution
was tested for cyclic AMP levels by a competition protein binding
assay. Samples of cyclic AMP standard (0–10 pmoles) were added
to each test tube containing [3H] cyclic AMP and incubation buffer
(trizma base 0.1 M, aminophylline 8.0mM, 2-mercaptoethanol
6.0mM, pH 7.4). The binding protein prepared from beef adrenals
was added to the samples previously incubated at 4 C for 150min,
and, after the addition of charcoal, was centrifuged at 2000 g for
10min. The clear supernatant was counted in a Scintillation
Counter Packard Tri Carb 2810 TR with an efficiency of 58%.
Data analysis
The protein concentration was determined according to a Bio-Rad
method56 with bovine albumin as a standard reference. Inhibitory
binding constant (Ki) values were calculated from those of IC50
according to Cheng & Prusoff equation Ki¼ IC50/(1þ [C]/KD),
where [C] is the concentration of the radioligand and KD its dis-
sociation constant57. A weighted non-linear least-squares curve fit-
ting program LIGAND58 was used for computer analysis of
inhibition experiments. IC50 values obtained in cyclic AMP assay
were calculated by non-linear regression analysis using the equa-
tion for a sigmoid concentration–response curve (Graph-PAD
Prism, San Diego, CA).
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